Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5523896 | Best Practice & Research Clinical Haematology | 2016 | 7 Pages |
Abstract
Whether patients with acute myeloid leukemia (AML) should receive routine consolidation chemotherapy prior to transplant remains a significant question. Consolidation therapy may be advisable in the face of transplant delays, such as donor identification, insurance clearance, or transplant center scheduling, to prevent relapse prior to transplant. However, in cases where physicians have a choice, the question of the value of consolidation chemotherapy continues to be debated. This paper reviews the value of consolidation therapy in 4 different transplant settings.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Frederick R. Appelbaum,